BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, October 12, 2024
See today's BioWorld
Home
» With no drugs on CMS’ list, Astellas withdraws IRA challenge
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
With no drugs on CMS’ list, Astellas withdraws IRA challenge
Sep. 7, 2023
By
Mari Serebrov
No Comments
Astellas Pharma US Inc. voluntarily withdrew its constitutional challenge Sept. 6 to the Inflation Reduction Act’s (IRA) drug price negotiations.
BioWorld
Regulatory
U.S.
CMS